Stockreport

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress

Organovo Holdings, Inc.  (ONVO) 
NASDAQ:AMEX Investor Relations: organovo.com/about/contact/investor-relations
PDF SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammator [Read more]